The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

New techniques and devices made headway in tough treatment scenarios, and guidelines stressed the need for collaborative care ...

The year saw much-anticipated data on the value of early TAVI vs surveillance, plus two new tricuspid device approvals.

More than ever, early-career physicians are looking for ways to fill gaps left by traditional education while maximizing ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.